<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="63070"><DrugName>BIM-21863</DrugName><DrugSynonyms><Name><Value>BIM-21863</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ghrelin receptor antagonist (obesity), Ipsen</Value></Name></DrugSynonyms><CompanyOriginator id="17259">Ipsen</CompanyOriginator><CompaniesSecondary><Company id="17259">Ipsen</Company></CompaniesSecondary><CrossReferences><SourceEntity id="17259" type="Company"><TargetEntity id="4295868520" type="organizationId">Ipsen SA</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="7794" type="Action"><TargetEntity id="1864" type="Mechanism">GHS Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00812" type="ciTarget"><TargetEntity id="122145728026933" type="siTarget">Growth hormone secretagogue receptor type 1</TargetEntity><TargetEntity id="310" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><IndicationsSecondary><Indication id="238">Obesity</Indication></IndicationsSecondary><ActionsPrimary><Action id="7794">Ghrelin receptor antagonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-08-24T13:25:25.000Z</LastModificationDate><ChangeDateLast>2009-09-22T17:02:00.000Z</ChangeDateLast><AddedDate>2009-04-06T16:13:53.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17259" linkType="Company"&gt;Ipsen&lt;/ulink&gt; (formerly Beaufour-Ipsen) was investigating BIM-21863, an analog of full-length human ghrelin that acts as a ghrelin receptor (GhrR) antagonist, for the potential treatment of obesity [&lt;ulink linkID="998507" linkType="Reference"&gt;998507&lt;/ulink&gt;], [&lt;ulink linkID="997874" linkType="Reference"&gt;997874&lt;/ulink&gt;]. However, development is presumed to have discontinued by December 2005 [&lt;ulink linkID="998507" linkType="Reference"&gt;998507&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By December 2005, preclinical data had been published for which showed that the drug inhibited growth hormone (GH) secretion in vivo, however, it stimulated weight gain suggesting that it might have acted on an unknown GhrR. In the medial arcuate nucleus it acted as an antagonist of ghrelin-induced Fos protein immunoreactivity (Fos-IR) and in the dorsal median hypothalamus (DMH) both ghrelin and BIM-28163 upregulated Fos-IR.  Administration of  BIM-21863 and ghrelin resulted in the same level of Fos-IR in the DMH, which suggested that both the compounds acted at the same receptor [&lt;ulink linkID="998507" linkType="Reference"&gt;998507&lt;/ulink&gt;]. In March 2009, similar data were presented at IBC's seventh annual Targeting Metabolic Disorders Conference in Boston, MA. BIM-21863 had respective binding and functional Ki values of 28 and 19 nM at the GhrR. It was reiterated that the increase in body weight observed was thought to be due to an action at an unknown GhrR; this was given as the reason that the program had been discontinued [&lt;ulink linkID="997874" linkType="Reference"&gt;997874&lt;/ulink&gt;],&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17259">Ipsen</Company><Country id="FR">France</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2005-12-31T00:00:00.000Z</StatusDate><Source id="998507" type="SERIAL"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><Targets><Target id="PTGT-00812"><Name>Ghrelin receptor</Name><SwissprotNumbers><Swissprot>O08725</Swissprot><Swissprot>Q92847</Swissprot><Swissprot>Q95254</Swissprot><Swissprot>Q99P50</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>